Therapeutic implications of cholesteryl ester transfer protein inhibitors in hyperlipidemia and low high-density lipoprotein-cholesterolemia

Current Opinion in Investigational Drugs

Volumn 4, Issue 3, 2003, Pages 291-297

  Inazu, Akihiro ^a   Mabuchi, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Cholesteryl ester transfer protein; High density lipoprotein; Inhibitor; Reverse cholesterol transport

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; AMINO ALCOHOL DERIVATIVE; ATORVASTATIN; CETI 1 VACCINE; CHOLESTEROL DERIVATIVE; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PNU 617; PROTEIN INHIBITOR; SC 71952; SC 795; SULFUR DERIVATIVE; TETRAHYDROQUINOLINE DERIVATIVE; TETRALIN DERIVATIVE; TORCETRAPIB; TRIACYLGLYCEROL; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

AORTA ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTER TRANSFER PROTEIN DEFICIENCY; CHOLESTEROL INTAKE; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; RABBIT; REVIEW; RISK FACTOR;

ANIMALS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; GLYCOPROTEINS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS;

EID: 0038417041     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Inazu A, Koizumi J, Mabuchi H: Cholesteryl ester transfer protein and atherosclerosis. Curr Opin Lipidol (2000) 11(4):389-396.
2. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR: Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med (1990) 323(18):1234-1238.
3. Tato F, Vega GL, Tall AR, Grundy SM: Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol (1995) 15(1):112-120.
4. Inazu A, Koizumi J, Mabuchi H, Kajinami K, Takeda R: Enhanced cholesteryl ester transfer protein activities and abnormalities of high density lipoproteins in familial hypercholesterolemia. Horm Metab Res (1992) 24(6):284-288.
5. Eisenberg S: Preferential enrichment of large-sized very low density lipoprotein populations with transferred cholesteryl esters. J Lipid Res (1985) 26(4):487-494.
6. Bagdade JD, Ritter MC, Subbaiah PV: Accelerated cholesteryl ester transfer in plasma of patients with hypercholesterolemia. J Clin Invest (1991) 87(4):1259-1265.
7. Lassel TS, Guerin M, Auboiron S, Chapman MJ, Guy-Grand B: Preferential cholesteryl ester acceptors among triglyceride-rich lipoproteins during alimentary lipemia in normolipidemic subjects. Arterioscler Thromb Vasc Biol (1998) 18(1):65-74.
8. Mann CJ, Yen FT, Grant AM, Bihain BE: Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest (1991) 88(6):2059-2066.
9. Guerin M, Egger P, Soudant C, Le Goff W, Van Tol A, Dupuis R, Chapman MJ: Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state. J Lipid Res (2002) 43(10):1652-1660.
10. Guerin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, Chapman MJ: Atherogenic role of elevated CE transfer from HDL to VLDL1 and dense LDL in type 2 diabetes: Impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol (2001) 21(2):282-288.
11. Moriyama Y, Okamura T, Inazu A, Doi M, Iso H, Mouri Y, Ishikawa Y, Suzuki H, Iida M, Koizumi J, Mabuchi H, Komachi Y: A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency. Prev Med (1998) 27(5 Pt 1):659-667.
12. Ikewaki K, Nishiwaki M, Sakamoto T, Ishikawa T, Fairwell T, Zech LA, Nagano M, Nakamura H, Brewer HB Jr, Rader DJ: Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J Clin Invest (1995) 96(3):1573-1581.
13. Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, Kamada M, Mizushima A: Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem (1998) 273(9):5033-5036.
14. Ohta T, Nakamura R, Takata K, Saito Y, Yamashita S, Horiuchi S, Matsuda I: Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency. J Lipid Res (1995) 36(4):696-704.
15. Zhang Z, Yamashita S, Hirano K, Nakagawa-Toyama Y, Matsuyama A, Nishida M, Sakai N, Fukasawa M, Arai H, Miyagawa J, Matsuzawa Y: Expression of cholesteryl ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport. Atherosclerosis (2001) 159(1):65-75. Immunoreactive CETP was detected in coronary atherosclerotic lesions, especially in foam cells. Macrophages from CETP-deficient individuals have decreased cellular cholesterol efflux activity.
16. Miida T, Inano K, Yamaguchi T, Tsuda T, Okada M: LpA-I levels do not reflect pre β1-HDL levels in human plasma. Atherosclerosis (1997) 133(2):221-226.
17. Sawada S, Sugano M, Makino N, Okamoto H, Tsuchida K: Secretion of preβ HDL increases with the suppression of cholesteryl ester transfer protein in Hep G2 cells. Atherosclerosis (1999) 146(2):291-298.
18. Kobayashi J, Okamoto H, Otabe M, Bujo H, Saito Y: Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J744 macrophage. Atherosclerosis (2002) 162(1): 131-135. In rabbits given JTT-705, the function of reducing CE in macrophages was maintained in HDL, which correlates with increased HDL3.
19. Zhang C, Zhuang Y, Qiang H, Liu X, Xu R, Wu Y: Relationship between endogenous estrogen concentrations and serum cholesteryl ester transfer protein concentrations in Chinese women. Clin Chim Acta (2001) 314(1-2): 77-83.
20. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G, Tybjaerg-Hansen A: Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation (2000) 101(16):1907-1912.
21. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG: Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study. Circulation (2000) 102 (18):2197-2203.
22. Cazita PM, Berti JA, Aoki C, Gidlund M, Harada LM, Nunes VS, Quintao ECR, Oliveira HCF: Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice. J Lipid Res (2003) 44(1):33-40. This study addressed the possibility that the CETP gene and estrogen interact. CETP deficiency increased atherosclerosis in ovariectomized mice, which was mediated by increased CE uptake and decreased cholesterol efflux activity in macrophages, as well as increased plasma levels of atherogenic lipoproteins.
23. Christison JK, Rye K-A, Stocker R: Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein. J Lipid Res (1995) 36(9):2017-2026.
24. Helisten H, Hockerstedt A, Wahala K, Tiitinen A, Adlercreutz H, Jauhiainen M, Tikkanen MJ: Accumulation of high-density lipoprotein-derived estradiol-17β fatty acid esters in low-density lipoprotein particles. J Clin Endocrinol Metab (2001) 86(3):1294-1300. Estrogen ester in HDL could be transferred to LDL through a CETP-mediated mechanism. LDL oxidation susceptibility was enhanced in postmenopausal women, which was possibly exaggerated by CETP deficiency.
25. Huang Z, Inazu A, Kawashira MA, Nohara A, Higashikata T, Mabuchi H: Dual effects on HDL metabolism by cholesteryl ester transfer protein inhibition in HepG2 cells. Am J Physiol Endocrinol Metab (2003): 4532002. This study indicates that hepatic CETP inhibition with antisense oligonucleotide could increase levels of HDL through increased apoAl secretion, increased cellular cholesterol efflux, and decreased selective uptake of cholesteryl ester from HDL.
26. Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD, Pettey CL, Adari H, Hammond RA, Beattie DT, Callow AD et al: Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol (2002) 20(9):2106-2122.
27. Shinkai H: Cholesteryl ester transfer protein inhibitors. Exp Opin Ther Pat (2001) 11(5):739-745.
28. Hope HR, Heuvelman D, Duffin K, Smith C, Zablocki J, Schilling R, Hegde S, Lee L, Witherbe B, Baganoff M, Bruce C et al: Inhibition of cholesteryl ester transfer protein by substituted dithiobisnicotinic acid dimethyl ester: Involvement of a critical cysteine. J Lipid Res (2000) 41(10):1604-1614.
29. Connolly DT, Whiterbee BJ, Melton MA, Durley RC, Grapperhaus ML, McKinnis BR, Vernier WF, Babler MA, Shieh JJ, Smith ME, Sikorski JA: Stereospecific inhibition of CETP by chiral N,N-disubstituted trifluoro-3-amino-2-propanols. Biochemistry (2000) 39(45):13870-13879.
30. Epps DE, Vosters AF: The essential role of a free sulfhydryl group in blocking the cholesteryl site of cholesteryl ester transfer protein (CETP). Chem Phys Lipids (2002) 114(2):113-122.
31. Shinkai H, Maeda K, Yamasaki T, Okamoto H, Uchida I: Bis (2-(acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. J Med Chem (2000) 43(19):3566-3572.
32. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature (2000) 406(6792):203-207.
33. Shimoji B, Zhang B, Ping F, Saku K: Metabolic background modulates the effects of CETP inhibitor on the in vivo kinetics of apo A-1. Circulation (2000) 106:Abs II-183.
34. Huang Z, Inazu A, Nohara A, Higashikata T, Mabuchi H: Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci (2002) 103(6):587-594. CETP inhibition did not reduce atherosclerosis in cholesterol-fed rabbits in which non-HDL cholesterol was inadequately decreased. This study indicates that more research is needed on the mechanisms of TG metabolism and post-prandial hyperlipidemia when CETP is inhibited.
35. De Grooth GJ, Kuivenhoven JA, Stalenhoef AFH, De Graaf J, Zwinderman AH, Posma JL, Va Tol A, Kastelein JJP: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: A randomized phase II dose-response study. Circulation (2000) 105(18):2159-2165. This is the first clinical trial on JTT-705 reported. JTT-705 clearly increased HDL-C levels and decreased plasma CETP activity. The drug increase HDL3 as well as HDL2. A mild reduction of LDL was observed, especially in individuals with baseline LDL-C > 170 mg/dl.
36. Durley RC, Grapperhaus ML, Hickory BS, Massa MA, Wang JL, Spangler DP, Mischke DA, Parnas BL, Fobian YM, Rath NP, Honda DD et al: Chiral N,N-disubstituted trifluoro-3-amino-2-propanols are potent inhibitors of cholesteryl ester transfer protein. J Med Chem (2002) 45(18):3891-3904.
37. Ishikawa Y, Ito K, Akasaka Y, Ishii T, Masuda T, Zhang L, Akishima Y, Kiguchi H, Nakajima K, Hata Y: The distribution and production of cholesteryl ester transfer protein in the human aortic wall. Atherosclerosis (2001) 156(1):29-37.
38. Gillian-Daniel DL, Bates PW, Tebon A, Attie AD: Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B. Proc Natl Acad Sci USA (2002) 99(7):4337-4342.
39. Ritsch A, Drexel H, Amann FW, Pfeifhofer C, Patsch JR: Deficiency of cholesteryl ester transfer protein. Description of the molecular defect and the dissociation of cholesteryl ester and triglyceride transport in plasma. Arterioscler Thromb Vasc Biol (1997) 17(12):3433-3441.
40. Pfizer Inc: Pfizer sees sustained, strong performance as broad and deep product line, new product pipeline, profit margin expansion and strategic alliances drive growth. Press Release (2000) 11 December.
41. Pfizer Inc: Wall street analysts meeting. Company Communication (2000) 11 December.
42. Kulju K, Beall MA, Whysall C: Company update: Pfizer - Sustaining industry-leading earnings growth performance. Credit Suisse First Boston Corporation (2001) 21 December.
43. Avant Immunotherapeutics Inc: AVANT announces preliminary results of phase I extension study of cholesterol management agent, CETi-1. Press Release (2001) 21 February.
44. Davidson MH, Wheeler A, Rittershaus C, Emmett C, Umporowicz D, Maki KC: A phase I trial of an immunotherapeutic approach for managing low plasma HDL-C. Int Symp On Drugs Affect Lipid Metab (2001):P35.
45. Dietschy JM, Turley SD: Control of cholesterol turnover in the mouse. J Biol Chem (2002) 277(6):3801-3804.
46. Robins SJ, Fasulo JM: High density lipoproteins, but not other lipoproteins, provide a vehicle for sterol transport to bile. J Clin Invest (1997)(3):380-384.
47. Foger B, Chase M, Amar MJ, Vaisman BL, Shamburek RD, Paigen B, Fruchart-Najib J, Paiz JA, Koch CA, Hoyt RF, Brewer HB Jr et al: Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem (1999) 274(52):36912-36920.
48. Hayek T, Masucci-Magoulas L, Jiang X, Walsh A, Rubin E, Breslow JL, Tall AR: Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest (1995) 96(4):2071-2074.
49. Haraki T, Inazu A, Yagi K, Kajinami K, Koizumi J, Mabuchi H: Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer protein deficiency. Atherosclerosis (1997) 132(2):229-236.
50. Bruce C, Sharp DS, Tall AR: Relationship of HDL and coronary heart disease to a common amino acid polymorphism in the cholesteryl ester transfer protein in men with and without hypertriglyceridemia. J Lipid Res (1998) 39(5):1071-1078.
51. Desai K, Bruckdorfer R, Hutton RA, Owen JS: Binding of apoE-rich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonist-induced platelet aggregation. J Lipid Res (1989) 30(6):831-840.
52. Espand RM, Stafford A, Leon B, Lock PE, Tytler EM, Segrest JP, Anantharamaiah GM: HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb (1994) 14(11):1175-1783.
53. Blackburn WD Jr, Dohlman JG, Venkatachalapathi YV, Pillion DJ, Koopman WJ, Segrest JP, Anantharamaiah GM: Apolipoprotein A-I decreases neutrophil degranulation and superoxide production. J Lipid Res (1991) 32(12):1911-1918.
54. Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE: Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol (1991) 68(15):1425-1430.
55. Paka L, Kako Y, Obunike JC, Pillarisetti S: Apolipoprotein E containing high density lipoprotein stimulates endothelial production of heparan sulfate rich in biologically active heparin-like domains. A potential mechanism for the anti-atherogenic actions of vascular apolipoprotein E. J Biol Chem (1999) 274(8):4816-4823.
56. Olin-Lewis K, Benton JL, Rutledge JC, Baskin DG, Wight TN, Chait A: Apolipoprotein E mediates the retention of high-density lipoproteins by mouse carotid arteries and cultured arterial smooth muscle cell extracellular matrices. Circ Res (2002) 90(12):1333-1339. HDL together with apoE, which is increased in CETP deficiency, was trapped in the vascular extracellular matrix, indicating that HDL with apoE has direct effects on the artery wall. However, whether these particles are anti- or pro-atherogenic, is not yet known.
57. Tato F, Vega GL, Grundy SM: Bimodal distribution of cholesteryl ester transfer protein activities in normotriglyceridemic men with low HDL cholesterol concentrations. Arterioscler Thromb Vasc Biol (1995) 15(4):446-451.
58. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR: Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest (1996) 97(12):2917-2923.
59. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR: Cholesteryl ester transfer protein: A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 23(2):160-167.